CHINA BIOLOGIC PRODUCTS, INC. (NASDAQ:CBPO) Files An 8-K Submission of Matters to a Vote of Security Holders

ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

China Biologic Products, Inc. (the Company) held its 2017 Annual
Meeting of Stockholders (the Annual Meeting) on Friday, June 30,
2017 (Beijing time). Proxies for the Annual Meeting were
solicited to the Companys proxy statement filed on May 19, 2017
with the Securities and Exchange Commission (the Proxy
Statement).

The Companys stockholders considered five proposals, each of
which is described in the Proxy Statement. A total of 23,944,222
shares were represented in person or by proxy, or 88.0% of the
total shares outstanding as of May 17, 2017, the record date of
the Annual Meeting. The final results of votes with respect to
the proposals submitted for stockholder vote at the Annual
Meeting are set forth below.

Proposal No. 1 Election of directors

Stockholders elected Sean Shao, Wenfang Liu and David Hui Li as
Class II directors for a three-year term as follows:

Proposal No. 2 Ratification of selection of
independent auditors

Stockholders ratified the selection of KPMG Huazhen LLP as the
independent registered public accounting firm of the Company for
the fiscal year ending December 31, 2017.

Proposal No. 3 Advisory vote to approve executive
compensation

Stockholders approved the compensation of our named executive
officers as disclosed in the Proxy Statement.

Proposal No. 4 Advisory vote on the frequency of an
advisory vote on executive compensation

Stockholders approved the one-year interval for the advisory vote
on executive compensation.

In light of the results of the stockholder vote on the frequency
of future advisory votes on the compensation of the Companys
named executive officers, and consistent with the Companys
recommendation, the Companys Board of Directors has determined
that the Company will hold an advisory vote on executive
compensation annually until the next required vote on the
frequency of future advisory votes on the compensation of the
Companys named executive officers.

Proposal No. 5 Adoption of the merger
agreement

Stockholders approved and adopted the agreement and plan of
merger by and between the Company and China Biologic Products
Holdings, Inc., an exempted company incorporated under the laws
of the Cayman Islands and a wholly owned subsidiary of the
Company, to which the Company will merge with and into China
Biologic Products Holdings, Inc. The Company is proceeding with
the completion of the transaction and expects the merger to
become effective during the third quarter of 2017.

There were no broker non-votes for any of the proposals submitted
for stockholder vote at the Annual Meeting.

About CHINA BIOLOGIC PRODUCTS, INC. (NASDAQ:CBPO)

China Biologic Products, Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories. Its principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through approximately two subsidiaries, namely, Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co., Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co., Ltd., a plasma products company. Its products also include Human rabies immunoglobulin, Human tetanus immunoglobulin, Placenta polypeptide, Factor VIII and Human prothrombin complex concentrate.